Complement Inhibitors in Generalized Myasthenia Gravis: Comparison of Administration Schedules, Efficacy, and Safety
Journal of Clinical Medicine · 19.11.2025 · 14 (22) · 8205
DOI: 10.3390/jcm14228205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.11.2025. Verfasst von Giuseppe Di Martino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, 90129 Palermo, Italy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Eculizumab, Ravulizumab, and Zilucoplan are inhibitors of terminal complement protein C5 (C5IT) approved for the treatment of generalized Myasthenia Gravis (gMG). The aim of this study is to compare the administration schedules, efficacy, and safety of these new biological therapies in a real-life setting.
Methods
We enrolled 31 patients with gMG who received C5IT (Eculizumab: 7 patients; Ravulizumab: 11 patients; Zilucoplan: 13 patients). We gathered demographic, clinical data by the difference between scores at baseline (T0) and after follow-up for the MG-ADL, QMG, and MGC scales.
Results
All C5IT demonstrated similar clinical efficacy, resulting in a statistically significant reduction in clinical scales scores for the MG-ADL (F = 14.7; p < 0.001), QMG (F = 14.78; p < 0.001), and MGC (F = 9.466; p < 0.001), with no significant differences among drugs (p > 0.05). No significant differences were highlighted in terms of MSE (p > 0.05). There was a decrease in the mean dose of steroid taken by patients in all three treatment groups (Eculizumab: −37%; Ravulizumab: −62%; Zilucoplan: −37%, at W34 compared to baseline). No myasthenic crises requiring hospitalization occurred during follow-up. Most of the reported adverse events were mild to moderate; the more severe events included one case of Stevens–Johnson syndrome (Ravulizumab) and episodes of pneumonia (Eculizumab, Ravulizumab).
Conclusions
The comparison of C5IT did not bring out significant differences in terms of clinical efficacy and safety, representing a valid therapeutic option when traditional therapies fail to control disease symptoms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, 90129 Palermo, Italy.
- Unità Operativa Complessa Farmacia, Azienda Universitaria Ospedaliera Policlinico P. Giaccone Hospital, 90129 Palermo, Italy.
ORCID-Profile: Simona Maccora, Salvatore Maria Lima, Filippo Brighina, Vincenzo Di Stefano
Zitieren
APA
Di Martino, G., Rini, N., Bonaventura, A., Trovato, M., Maccora, S., Lima, S. M., La Seta, C., Brighina, F., & Di Stefano, V. (2025). Complement Inhibitors in Generalized Myasthenia Gravis: Comparison of Administration Schedules, Efficacy, and Safety. Journal of Clinical Medicine, 14(22), 8205. https://doi.org/10.3390/jcm14228205
Vancouver
Di Martino G, Rini N, Bonaventura A, Trovato M, Maccora S, Lima SM, et al. Complement Inhibitors in Generalized Myasthenia Gravis: Comparison of Administration Schedules, Efficacy, and Safety. Journal of Clinical Medicine. 2025;14(22):8205. doi:10.3390/jcm14228205
BibTeX
@article{DiMartino2025,
author = {Di Martino, Giuseppe and Rini, Nicasio and Bonaventura, Alessia and Trovato, Mauro and Maccora, Simona and Lima, Salvatore Maria and La Seta, Concetta and Brighina, Filippo and Di Stefano, Vincenzo},
title = {Complement Inhibitors in Generalized Myasthenia Gravis: Comparison of Administration Schedules, Efficacy, and Safety},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {22},
pages = {8205},
doi = {10.3390/jcm14228205}
}
EUVIMED